![]()
|
|
||||||||
J. Biol. Chem., Vol. 277, Issue 12, 9790-9799, March 22, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
,
From the Department of Pharmacology, Lineberger Comprehensive
Cancer Center, University of North Carolina,
Chapel Hill, North Carolina 27599-7295
Activated Ras but not Raf can transform RIE-1 and
other epithelial cells, indicating the critical importance of
Raf-independent effector function in Ras transformation of epithelial
cells. To elucidate the nature of these Raf-independent activities, we
utilized representational difference analysis to identify genes
aberrantly expressed by Ras through Raf-independent mechanisms in RIE-1
cells. We identified a total of 22 genes, both known and novel, whose expression was either activated (10) or abolished (12) by Ras but not
Raf. The genes up-regulated encode proteins involved in protein or DNA
synthesis, regulation of protease activity, or ligand binding, whereas
those genes down-regulated encode actin cytoskeletal-, extracellular
matrix-, and gap junction-associated proteins, and transmembrane
receptor- or cytokine-like proteins. These results suggest that a key
function of Raf-independent signaling involves deregulation of gene
expression. We further characterized transgelin as a gene whose
expression was abolished by Ras. Transgelin was identified previously
as a protein whose expression was lost in virally transformed cell
lines. We show that this loss is regulated at the level of gene
expression and that both Raf-dependent and Raf-independent
pathways are required to cause Ras down-regulation of transgelin in
RIE-1 cells, whereas Raf alone is sufficient to cause its loss in NIH
3T3 fibroblasts. We also found that Ras-dependent and
Ras-independent mechanisms can cause the down-regulation of transgelin
in human breast and colon carcinoma cells lines and patient-derived
tumor samples. We conclude that loss of transgelin gene expression may
be an important early event in tumor progression and a diagnostic
marker for breast and colon cancer development.
To whom correspondence should be addressed: Lineberger
Comprehensive Cancer Center, CB 7295, University of North Carolina, Chapel Hill, NC 27599-7295. Tel.: 919-962-1057; Fax: 919-966-0162; E-mail: shieldsj@med.unc.edu.
This article has been cited by other articles:
![]() |
H. Yu, M. Konigshoff, A. Jayachandran, D. Handley, W. Seeger, N. Kaminski, and O. Eickelberg Transgelin is a direct target of TGF-{beta}/Smad3-dependent epithelial cell migration in lung fibrosis FASEB J, June 1, 2008; 22(6): 1778 - 1789. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Zer, G. Sachs, and J. M. Shin Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-{alpha} signaling Physiol Genomics, October 19, 2007; 31(2): 343 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-S. Tsai, S.-M. Hwang, K.-D. Chen, Y.-S. Lee, L.-W. Hsu, Y.-J. Chang, C.-N. Wang, H.-H. Peng, Y.-L. Chang, A.-S. Chao, et al. Functional Network Analysis of the Transcriptomes of Mesenchymal Stem Cells Derived from Amniotic Fluid, Amniotic Membrane, Cord Blood, and Bone Marrow Stem Cells, October 1, 2007; 25(10): 2511 - 2523. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Skobeleva, S. Menon, L. Weber, E. A. Golemis, and V. Khazak In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway- and microtubule-targeting inhibitors Mol. Cancer Ther., March 1, 2007; 6(3): 898 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Shields, N. E. Thomas, M. Cregger, A. J. Berger, M. Leslie, C. Torrice, H. Hao, S. Penland, J. Arbiser, G. Scott, et al. Lack of Extracellular Signal-Regulated Kinase Mitogen-Activated Protein Kinase Signaling Shows a New Type of Melanoma Cancer Res., February 15, 2007; 67(4): 1502 - 1512. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Yang, Y.-J. Chang, H. Miyamoto, J. Ni, Y. Niu, Z. Chen, Y.-L. Chen, J. L. Yao, P. A. di Sant'Agnese, and C. Chang Transgelin Functions as a Suppressor via Inhibition of ARA54-Enhanced Androgen Receptor Transactivation and Prostate Cancer Cell Growth Mol. Endocrinol., February 1, 2007; 21(2): 343 - 358. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. R. Nair, J. Solway, and D. D. Boyd Expression Cloning Identifies Transgelin (SM22) as a Novel Repressor of 92-kDa Type IV Collagenase (MMP-9) Expression J. Biol. Chem., September 8, 2006; 281(36): 26424 - 26436. [Abstract] [Full Text] [PDF] |
||||
![]() |
K Birkenkamp-Demtroder, S H Olesen, F B Sorensen, S Laurberg, P Laiho, L A Aaltonen, and T F Orntoft Differential gene expression in colon cancer of the caecum versus the sigmoid and rectosigmoid Gut, March 1, 2005; 54(3): 374 - 384. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. K. Vanaja, J. C. Cheville, S. J. Iturria, and C. Y. F. Young Transcriptional Silencing of Zinc Finger Protein 185 Identified by Expression Profiling Is Associated with Prostate Cancer Progression Cancer Res., July 15, 2003; 63(14): 3877 - 3882. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |